Skip to main content
. 2018 Sep 29;13:172. doi: 10.1186/s13023-018-0914-3

Table 2.

Summary of key model inputs: probabilities, costs and utilities. Transition probabilities are presented for each model transition, including those from a Markov state (e.g. Mild CF) to transition states (e.g. Pulmonary Exacerbation)

Variable Base-case One-way Source
Low High
Probabilities
 Mild to Death Age-specific mortality for CF population [3]
 Mild to Pulmonary Exacerbation 0.3213 0.2571 0.3856 [16]
 Pulmonary Exacerbation in Mild to Death 0.001 0.0008 0.0012 Assumption
 Pulmonary Exacerbation in Mild to Moderate 0.0697 0.0558 0.0837 [14, 15]
 No Pulmonary Exacerbation in Mild to Moderate 0.0307 0.0245 0.0368 [14, 15]
 Moderate to Death Age-specific mortality for CF population [3]
 Moderate to Pulmonary Exacerbation 0.5748 0.4599 0.6898 [16]
 Pulmonary Exacerbation in moderate to Death 0.001 0.0008 0.0012 Assumption
 Pulmonary Exacerbation in Moderate to Severe 0.0617 0.0493 0.074 [14, 15]
 No Pulmonary Exacerbation in Moderate to Severe 0.0279 0.0223 0.0335 [14, 15]
 Severe to Death Age-specific mortality for CF population [3]
 Severe to Pulmonary Exacerbation 0.6794 0.5435 0.8153 [16]
 Pulmonary Exacerbation in severe to death 0.2174 0.1739 0.2609 [18]
 Transplant to Death 0.297 0.2376 0.3564 [17]
 Pulmonary Exacerbation in Severe to Transplant 0.078 0.0624 0.0937 [17]
 No Pulmonary Exacerbation in Severe to Transplant 0.078 0.0624 0.0937 [17]
 Post-transplant to Death Calculated year-wise [19]
Lumacaftor/Ivacaftor:
 Moderate to Mild without Pulmonary Exacerbation 0.0935 0.0748 0.1123 [5, 14, 15]
 Severe to Moderate without Pulmonary Exacerbation 0.5517 0.4414 0.6621 [5, 14, 15]
 Moderate to Mild with Pulmonary Exacerbation 0.1045 0.0836 0.1254 [5, 14, 15]
 Severe to Moderate with Pulmonary Exacerbation 0.5455 0.4364 0.6545 [5, 14, 15]
 Relative risk for Pulmonary Exacerbation (Lumacaftor/Ivacaftor vs Placebo) 0.74 0.592 0.89 [5]
Costs (USD-2016)
 Lumacaftor/ivacaftor 188,660.43 150,928.34 226,392.51 [9, 20]
 Mean cost of Pulmonary Exacerbation in Mild 2575.97 2575.97 30,949.79 [13]
 Mean cost of Pulmonary Exacerbation in Moderate 8371.90 8371.90 41,969.47 [13]
 Mean cost of Pulmonary Exacerbation in Severe 52,646.40 52,646.40 123,385.36 [13]
 Mild 7566.91 5121.17 30,267.65 [13]
 Moderate 9981.89 6709.60 39,927.54 [13]
 Severe 17,226.80 8688.16 68,907.21 [13]
 Transplant 1,056,002.23 844,801.78 1,267,202.67 [21]
 Post-transplant 87,945.85 (1st year) 70,356.68 105,535.02 [21, 22]
86,332.56 (2nd year onwards) 69,066.05 103,599.07 [22]
Utilities
 Mild 0.86 0.77 0.94 [23]
 Moderate 0.81 0.72 0.89 [23]
 Severe 0.64 0.57 0.7 [23]
 Post-transplant 0.83 0.74 0.91 [23]
 Pulmonary Exacerbation − 0.17 − 0.15 −0.19 [23]